2019
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
Oezkan F, He K, Owen D, Pietrzak M, Cho J, Kitzler R, Pearson R, Rusch V, Chaft J, Suh R, Blasberg J, Reckamp K, Raz D, Kneuertz P, Fiorillo L, Garon E, Nicholas A, Johnson A, Schulze K, Grindheim J, Banchereau R, Phan S, Bunn P, Kwiatkowski D, Johnson B, Kris M, Wistuba I, Lee J, Lozanski G, Carbone D. OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3. Journal Of Thoracic Oncology 2019, 14: s242-s243. DOI: 10.1016/j.jtho.2019.08.482.Peer-Reviewed Original ResearchResectable NSCLC patientsNeoadjuvant atezolizumabNSCLC patientsImmunophenotyping resultsInterim analysisAtezolizumabPatients
2009
Reduction of elevated plasma osteopontin levels with resection of non-small cell lung cancer (NSCLC)
Blasberg J, Pass H, Flores R, Donington J. Reduction of elevated plasma osteopontin levels with resection of non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: 11019-11019. DOI: 10.1200/jco.2009.27.15_suppl.11019.Peer-Reviewed Original ResearchNon-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerEarly-stage NSCLC patientsStage NSCLC patientsPlasma osteopontin levelsNSCLC patientsOPN levelsPlasma OPNOsteopontin levelsIndependent cohortElevated Plasma Osteopontin LevelsStage I patientsImpact of surgeryCell lung cancerResectable NSCLC patientsSignificant decreaseNSCLC correlatesFormer smokersI patientsPrognostic significanceValidation cohortLung cancerPatientsMultivariate analysis